AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27660194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline plus structured, tailored group physical exercise (S + EX)
Number of subjects: 0
Study 27660194 — intervention group
Group type: COMPARATOR
Intervention: Sertraline alone (S)
Number of subjects: 0
Study 24735707 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) combined with enhanced community services (ECS)
Number of subjects: 600
Study 24735707 — intervention group
Group type: COMPARATOR
Intervention: Enhanced community services (ECS) alone
Number of subjects: 600
Study 22947426 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir (100 mg twice daily)
Number of subjects: 303
Study 22947426 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir (1000 mg three times daily)
Number of subjects: 303
Study 20087154 — intervention group
Group type: COMPARATOR
Intervention: Abacavir (ABC)
Number of subjects: 21
Study 20087154 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 21
Study 20087154 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC) + Tenofovir disoproxil fumarate (TDF) dual-therapy
Number of subjects: 21
Study 18207225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 1.5 mg
Number of subjects: 22
Study 18207225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3 mg
Number of subjects: 22
Study 18207225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 18207225 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (3 mg, IV)
Number of subjects: 22
Study 15998547 — intervention group
Group type: EXPERIMENTAL
Intervention: Decubitus direct current treatment (DDCT)
Number of subjects: 63
Study 15998547 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 63
Study 12571204 — intervention group
Group type: COMPARATOR
Intervention: (123)I‐5‐I‐R91150
Number of subjects: 15
Study 10574383 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap pursuit tasks
Number of subjects: 0
Study 10574383 — intervention group
Group type: COMPARATOR
Intervention: Non-gap tasks
Number of subjects: 0
Study 10574383 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap tasks
Number of subjects: 0
Study 10574383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8818375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy administered by competent therapists (n = 30)
Number of subjects: 70
Study 8818375 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavior therapy administered by therapists of uncertain competence (n = 40)
Number of subjects: 70
Study 1549648 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with expectancy of enhanced performance (E(+))
Number of subjects: 56
Study 1549648 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with expectancy of impairment (E(-))
Number of subjects: 56
Study 1549648 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with no information (E(?))
Number of subjects: 56
Study 1549648 — intervention group
Group type: COMPARATOR
Intervention: Control group (E(0))
Number of subjects: 56
Study 4015285 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 150
Study 4015285 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 150
Study 4015285 — intervention group
Group type: COMPARATOR
Intervention: Oxprenolol 160 mg
Number of subjects: 150
Study 4015285 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg
Number of subjects: 150
Study 31614532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mung bean protein supplementation (18 g/day)
Number of subjects: 37
Study 31614532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no protein supplementation)
Number of subjects: 37
Study 30024639 — intervention group
Group type: EXPERIMENTAL
Intervention: AIBD plus treatment as usual (TAU)
Number of subjects: 72
Study 30024639 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 72
Study 27281561 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib treatment
Number of subjects: 60
Study 27281561 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC analysis at progression
Number of subjects: 60
Study 27281561 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 60
Study 27281561 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of cfDNA
Number of subjects: 60
Study 27281561 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of CTCs
Number of subjects: 60
Study 24140730 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 556
Study 24140730 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 556
Study 22564837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin administered intravenously for 3 days
Number of subjects: 200
Study 22564837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 200
Study 20587580 — intervention group
Group type: EXPERIMENTAL
Intervention: rs806381 polymorphism
Number of subjects: 783
Study 20587580 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1049353 polymorphism
Number of subjects: 783
Study 20587580 — intervention group
Group type: COMPARATOR
Intervention: None of the SNPs analysed
Number of subjects: 783
Study 19031133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track programs (FT); 44 cases
Number of subjects: 83
Study 19031133 — intervention group
Group type: COMPARATOR
Intervention: Control group; 39 cases
Number of subjects: 83
Study 15794443 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated pupillometer
Number of subjects: 20
Study 15794443 — intervention group
Group type: COMPARATOR
Intervention: Manual examination with a penlight or similar light source
Number of subjects: 20
Study 12214831 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of magnesium sulfate
Number of subjects: 401
Study 12214831 — intervention group
Group type: COMPARATOR
Intervention: Standard regime of magnesium sulfate
Number of subjects: 401
Study 10325275 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural cycles (n = 16)
Number of subjects: 11
Study 10325275 — intervention group
Group type: COMPARATOR
Intervention: Stimulated cycles (n = 25)
Number of subjects: 11
Study 8960845 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet control of NIDDM
Number of subjects: 1139
Study 1729588 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric consultation advising physicians on treatment
Number of subjects: 119
Study 1729588 — intervention group
Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 119
Study 1729588 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antidepressants (amitriptyline, imipramine, doxepin)
Number of subjects: 119
Study 1729588 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antidepressants (nortriptyline, desipramine, trazodone, fluoxetine)
Number of subjects: 119
Study 6431572 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine, sublingually
Number of subjects: 8
Study 6431572 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate by inhalation
Number of subjects: 8
Study 30781691 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education post
Number of subjects: 2123
Study 30781691 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk communication post
Number of subjects: 2123
Study 30781691 — intervention group
Group type: EXPERIMENTAL
Intervention: Post in the afternoon
Number of subjects: 2123
Study 30781691 — intervention group
Group type: EXPERIMENTAL
Intervention: Post in the evening
Number of subjects: 2123
Study 30781691 — intervention group
Group type: EXPERIMENTAL
Intervention: Video format
Number of subjects: 2123
Study 29482422 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine
Number of subjects: 211
Study 29482422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 27323615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine (2 mg/kg)
Number of subjects: 60
Study 27323615 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 25074865 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 0.25% topical solution
Number of subjects: 24
Study 25074865 — intervention group
Group type: COMPARATOR
Intervention: Finasteride 1 mg tablet
Number of subjects: 24
Study 22198445 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 106
Study 22198445 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 106
Study 22198445 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 106
Study 20339154 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with pravastatin (40 mg once daily)
Number of subjects: 508
Study 20339154 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment without pravastatin
Number of subjects: 508
Study 17010609 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2 gene expression
Number of subjects: 50
Study 17010609 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPO IIalpha and MAPT gene expression
Number of subjects: 50
Study 16137586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenhanced CT within 48 hours of admission
Number of subjects: 697
Study 16137586 — intervention group
Group type: COMPARATOR
Intervention: Nonenhanced CT over the subsequent 6 days
Number of subjects: 697
Study 11961331 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF-SnF2 mouthrinse (Meridol with and without 5% alcohol)
Number of subjects: 5
Study 11961331 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (CHX)
Number of subjects: 5
Study 11961331 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 5
Study 11329096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 49
Study 11329096 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg orally in the morning and placebo in the evening
Number of subjects: 49
Study 7553230 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta), retinoids (R), and tamoxifen (TAM)
Number of subjects: 49
Study 2258364 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 11
Study 7041752 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular endolymphatic shunt
Number of subjects: 30
Study 7041752 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) operation (regular mastoidectomy)
Number of subjects: 30
Study 31210498 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention including two education sessions and five telephone calls over two months
Number of subjects: 136
Study 31210498 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 136
Study 29101171 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE 4 × 4
Number of subjects: 13
Study 29101171 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE 16 × 1
Number of subjects: 13
Study 29101171 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study 27599329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 1% (4 mg/d)
Number of subjects: 121
Study 27599329 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol 0.1% (0.4 mg/d)
Number of subjects: 121
Study 27599329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10% (40 mg/d)
Number of subjects: 121
Study 27599329 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 121
Study 25058146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt diet (3.0 g/day of NaCl) for 7 days
Number of subjects: 42
Study 25058146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet (18.0 g/day of NaCl) for 7 days
Number of subjects: 42
Study 25058146 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet with potassium supplementation (18.0 g/day of NaCl + 4.5 g/day of KCl) for 7 days
Number of subjects: 42
Study 25058146 — intervention group
Group type: COMPARATOR
Intervention: All dietary interventions
Number of subjects: 42
Study 22297625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg IV plus haloperidol 2 mg IM (group DH)
Number of subjects: 135
Study 22297625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg IV plus ondansetron 4 mg IV (group DO)
Number of subjects: 135
Study 22297625 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 5 mg IV (group D)
Number of subjects: 135
Study 21175313 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib plus peginterferon alfa-2a (90 μg weekly)
Number of subjects: 636
Study 21175313 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (400 mg daily) alone
Number of subjects: 636
Study 21175313 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg daily)
Number of subjects: 636
Study 21175313 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg daily) plus cytarabine (20 mg/m² daily on days 15-28)
Number of subjects: 636
Study 21175313 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib plus peginterferon alfa-2a
Number of subjects: 636
Study 17704091 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend-controlled propofol/remifentanil anaesthetic regimen
Number of subjects: 48
Study 17704091 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 48
Study 15925768 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Haemetaporphyrin derivative (HpD) after surgical resection
Number of subjects: 136
Study 12488409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m² intravenously on days 1 to 5, every 28 days)
Number of subjects: 91
Study 12488409 — intervention group
Group type: COMPARATOR
Intervention: CVP (cyclophosphamide 750 mg/m² and vincristine 1.2 mg/m² intravenously on day 1, prednisone 40 mg/m² orally on days 1 to 5, every 21 days)
Number of subjects: 91
Study 12488409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m²)
Number of subjects: 91
Study 12488409 — intervention group
Group type: COMPARATOR
Intervention: CVP
Number of subjects: 91
Study 12488409 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine
Number of subjects: 91
Study 9577932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ky5-exposed workers
Number of subjects: 57
Study 9577932 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed workers
Number of subjects: 57
Study 8587758 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of 5% glucose water containing 4 g of regular instant coffee
Number of subjects: 93
Study 8587758 — intervention group
Group type: COMPARATOR
Intervention: Baseline: 500 ml of 5% glucose water
Number of subjects: 93
Study 8587758 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate coffee measurements
Number of subjects: 93
Study 2632448 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sulindac therapy
Number of subjects: 0
Study 2632448 — intervention group
Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 0
Study 592986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed bicycle with elevated legs and elastic stockings
Number of subjects: 0
Study 592986 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard method, usually walking)
Number of subjects: 0
Study 592986 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor cycle exercises
Number of subjects: 0
Study 592986 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 31315962 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study 31315962 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28657601 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic wine (AW)
Number of subjects: 0
Study 28657601 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirits (S)
Number of subjects: 0
Study 28657601 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic beer (AB)
Number of subjects: 0
Study 28657601 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic wine (NAW)
Number of subjects: 0
Study 28657601 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 0
Study 26237828 — intervention group
Group type: EXPERIMENTAL
Intervention: WCR plus TCM (insulin, isoniazid, rifampicin, pyrazinamide, ethambutol + Qi‐boosting and Yin‐nourishing decoction)
Number of subjects: 60
Study 26237828 — intervention group
Group type: COMPARATOR
Intervention: WCR (insulin, isoniazid, rifampicin, pyrazinamide, ethambutol)
Number of subjects: 60
Study 23483023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure preparation
Number of subjects: 198
Study 23483023 — intervention group
Group type: COMPARATOR
Intervention: PEG preparation
Number of subjects: 198
Study 21683993 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal disease (MD)
Number of subjects: 417
Study 21683993 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal peritoneal disease (APD)
Number of subjects: 417
Study 21683993 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdominal disease (UAD)
Number of subjects: 417
Study 21683993 — intervention group
Group type: COMPARATOR
Intervention: MD + APD (combined)
Number of subjects: 417
Study 19454924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 52
Study 19454924 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 52
Study 16674760 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-standardized acupuncture
Number of subjects: 28
Study 16674760 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 28
Study 15355454 — intervention group
Group type: COMPARATOR
Intervention: Fixed 10‐mg HC dose
Number of subjects: 20
Study 15355454 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight‐adjusted dosing
Number of subjects: 20
Study 15355454 — intervention group
Group type: EXPERIMENTAL
Intervention: Food taken before HC
Number of subjects: 20
Study 15355454 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cortisol measured 4 h after HC
Number of subjects: 20
Study 15355454 — intervention group
Group type: EXPERIMENTAL
Intervention: New thrice‐daily treatment regimen
Number of subjects: 20
Study 11318241 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session small-group cognitive-behavioral HIV risk reduction intervention
Number of subjects: 189
Study 11318241 — intervention group
Group type: COMPARATOR
Intervention: Time-matched comparison intervention
Number of subjects: 189
Study 9408337 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice operation
Number of subjects: 129
Study 9408337 — intervention group
Group type: COMPARATOR
Intervention: Bassini-Kirschner operation
Number of subjects: 129
Study 7508321 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation intervention (specific details not provided in the abstract)
Number of subjects: 0
Study 7508321 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided in the abstract)
Number of subjects: 0
Study 3310200 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg in the evening
Number of subjects: 336
Study 3310200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 31916142 — intervention group
Group type: EXPERIMENTAL
Intervention: High Physical and Sexual Violence and Injuries
Number of subjects: 659
Study 31916142 — intervention group
Group type: EXPERIMENTAL
Intervention: High Physical and Low Sexual Violence and Injuries
Number of subjects: 659
Study 31916142 — intervention group
Group type: COMPARATOR
Intervention: Low Physical and Sexual Violence
Number of subjects: 659
Study 28479016 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weight loss (4 weeks)
Number of subjects: 35
Study 28479016 — intervention group
Group type: COMPARATOR
Intervention: Gradual weight loss (8 weeks)
Number of subjects: 35
Study 28479016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 28479016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after weight stabilization
Number of subjects: 35
Study 26914668 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic pulmonary vein isolation and atrial appendage ligation (TPVIAL)
Number of subjects: 23
Study 26914668 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 23
Study 25073881 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental nursing intervention to help family caregivers manage post-cardiac surgery delirium
Number of subjects: 30
Study 25073881 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 30
Study 24373585 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency particle air filter
Number of subjects: 48
Study 24373585 — intervention group
Group type: COMPARATOR
Intervention: Control (no air filtration)
Number of subjects: 48
Study 20023437 — intervention group
Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 650
Study 20023437 — intervention group
Group type: COMPARATOR
Intervention: nevirapine
Number of subjects: 650
Study 18593799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity walking (75% of VO2peak)
Number of subjects: 14
Study 18593799 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking (50% of VO2peak)
Number of subjects: 14
Study 18593799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity walking (25% of VO2peak)
Number of subjects: 14
Study 18593799 — intervention group
Group type: EXPERIMENTAL
Intervention: All walking intensities
Number of subjects: 14
Study 16634072 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical treatment with Er:YAG laser (12.7 J/cm2)
Number of subjects: 12
Study 15292850 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (160 mg/d oral testosterone undecanoate for men, 80 mg/d for women, 563 kcal/d oral dietary supplements, exercise on ergometric bicycle 3 to 5 times a week)
Number of subjects: 200
Study 15292850 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 home visits for education)
Number of subjects: 200